Market Access/ Views & Analysis/ Views and analysis Why companies don’t submit to NICE Leela Barham HTA, NICE, Non-submissions 0 Comment In March 2022, Leela Barham argued that, in light of new highs in the number of non-submissions to Share X Why companies don’t submit to NICE https://pharmaphorum.com/market-access-2/why-companies-dont-submit-to-nice/
Market Access/ Views & Analysis/ Views and analysis The shadow of Brexit on speed of access Leela Barham Brexit, England, HTA, NICE, Non-submissions, Scotland, SMC 0 Comment No-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share X The shadow of Brexit on speed of access https://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
